1024px-Primary_biliary_cirrhosis_intermed_mag - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Calliditas takes control of Genkyotex: expanding the rare disease pipeline

1024px-Primary_biliary_cirrhosis_intermed_mag
Genkyotex’s Sextanaxib is a NOX 1 and 4 inhibitor being studied in Phase II studies for liver fibrosis associated with orphan disease primary biliary cholangitis. Credit: Nephron via Wikimedia.